BPA Call 36E79721A0003-36C26221N0861
Award Date 8/16/21
Potential Completion Date 7/22/22
Potential Value $28K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
La Vergne, TN 37086, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 awarded a $39,754.84 firm fixed price delivery order to Servier Pharmaceuticals LLC of Boston, Massachusetts for the drug ONCASPAR. The contract has a period of performance through May 15, 2020 and was awarded on May 8, 2020 without a set-aside designation. Servier Pharmaceuticals LLC will provide the specified pharmaceutical to the VA network to support healthcare services for veterans in...
- Servier Pharmaceuticals LLC was awarded a $29,816.13 firm fixed price delivery order against the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10. The order is for the pharmaceutical product ONCASPAR and has a period of performance through November 30, 2020. No set-aside designation was applied to this award. Servier Pharmaceuticals LLC will deliver the ordered products to the place of...
- This federal contract award is for the delivery of the cancer drug Iclusig (ponatinib) to the Department of Veterans Affairs Veterans Health Administration. The contract was awarded to the prime contractor Ariad Pharmaceuticals, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The contract was not set aside and was awarded under the General Services Administration (GSA) Pharmaceuticals and Drugs schedule, which allows government agencies to purchase drugs and...
- This is a federal contract award from the U.S. Department of Veterans Affairs (VA) to Novartis Pharmaceuticals Corporation, a foreign-owned, for-profit manufacturer of pharmaceutical goods. The contract, valued at $231,396.00, is a Delivery Order contract with a Firm Fixed Price pricing type. The contract is for the procurement of specialized medical treatments, such as cancer therapies and advanced pharmaceuticals, to support the VA's medical programs. The contract utilizes the...
- This federal contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Ariad Pharmaceuticals, Inc., a pharmaceutical company that provides cancer drugs through the GSA Pharmaceuticals and Drugs schedule. The contract is for the delivery of the cancer drug Iclusig (ponatinib) to VA hospitals and medical centers under Veterans Integrated Service Network 7. The contract was not set aside and has a potential value of $148,782.16. The contract is a BPA...
- This federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is for the supply of PHARMACY DRUGS, specifically oncology medications and other specialty drugs, to the U.S. Department of Veterans Affairs (VA). The $356,183.07 ceiling value contract was awarded on October 1, 2023 and has an ultimate completion date of September 30, 2024. This contract is a Delivery Order issued under Janssen Biotech's $3.1 billion multiple-award Federal Supply Schedule (FSS)...
- This delivery order contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Ariad Pharmaceuticals, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of prescription medications, specifically the cancer drugs Iclusig (ponatinib) and Lenvima (lenvatinib), to VA hospitals and medical centers. The contract has a firm fixed price with a potential value of $138,026.40 and was placed under the General Services...
- This is a federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer, to provide BALVERSA 4 MG, a cancer treatment drug, to the U.S. Department of Veterans Affairs (VA). The contract is a delivery order with a firm fixed price of $17,642.95 and an ultimate completion date of August 13, 2024. This award is associated with two larger contract vehicles - a $3.7 million single-award Blanket Purchase Agreement (BPA) established in...
- This is a delivery order award to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products, under the company's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. The contract, valued at $27,913.44, is for the supply of the oncology medication ICLUSIG (ponatinib) to the U.S. Department of Veterans Affairs (VA). The award is part of a larger Blanket Purchase Agreement (BPA) between Takeda and the VA National...
- The Department of Veterans Affairs (VA) awarded a $283,526.57 firm fixed price delivery order to Novartis Pharmaceuticals Corporation, a foreign-owned for-profit manufacturer, to provide the emergency cancer treatment Tisagenlecleucel under the VA's Federal Supply Schedule contract for pharmaceuticals and drugs. The delivery order was issued by the VA Veterans Health Administration's Veterans Integrated Service Network 9 and did not have a set-aside designation. Novartis holds a $5.4 billion...